Core Insights - The market potential for Atopic Dermatitis (AD) is significant, with a large patient population and unmet medical needs, particularly for effective and safe treatments [1][2] - The development of small molecules and biologics is entering a new phase, with several new therapies gradually being approved for AD treatment [2][3] - JAK inhibitors show excellent efficacy but have safety concerns, while TYK2 is emerging as a promising new option with potentially higher safety [3][4] - Biologics such as IL-4Rα and IL-31 demonstrate strong efficacy in improving skin lesions and alleviating itching, but there is still room for improvement compared to JAK inhibitors [4][5] - Dual and multi-target antibodies may offer a new approach by combining the advantages of different targets, with several companies already exploring this strategy [5] Group 1: Market Overview - Atopic Dermatitis (AD) is a chronic, recurrent inflammatory skin disease characterized by severe itching, affecting approximately 600-700 million patients globally, with around 67 million in China [1] - The demand for effective and safe medications is high due to the significant burden of the disease on patients' daily lives [1] Group 2: Treatment Landscape - Traditional therapies have poor safety profiles, leading to the emergence of biologics and small molecule targeted therapies over the past decade, with about a dozen products approved globally [2] - Current approved small molecule JAK inhibitors include Upadacitinib and Abrocitinib, but they carry safety warnings from the FDA [3] Group 3: Biologics Efficacy - Among the biologics, IL-4Rα and IL-13 show confirmed efficacy, while IL-31 is particularly effective in alleviating itching [4] - There is a notable difference in efficacy between biologics and JAK inhibitors, with Upadacitinib showing superior results in head-to-head studies [4] Group 4: Future Directions - The exploration of dual/multi-target antibodies aims to enhance treatment efficacy and extend dosing intervals, with several companies already developing such therapies [5] - Ongoing research into various targets may lead to improved outcomes for AD patients [5]